Compare iShares MSCI Indonesia ETF (EIDO) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Indonesia ETF vs Zoetis Inc — how do they compare? iShares MSCI Indonesia ETF trades at $12.18, while Zoetis Inc trades at $77 (market cap $31.25B). The key difference: Zoetis Inc pays a 2.84% dividend while iShares MSCI Indonesia ETF pays none, and iShares MSCI Indonesia ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| EIDO | ZTS | |
|---|---|---|
52-Week High | $19.22 | $156.76 |
52-Week Low | $10.80 | $71.91 |
Market Cap | — | $31.25B |
Sector | — | Health |
Enterprise Value | — | $38.54B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares MSCI Indonesia ETF (EIDO) trades at $12.205, up 1.12% on the day, while technical indicators signal a bearish trend with moving averages and an overbought short-term RSI. Recent news highlights Indonesia's economic initiatives, including a $15 billion AI-integrated free-meal plan and central bank rate hikes to support the currency. However, key financial ratios for the underlying fund holdings are unavailable in the provided data.
The outlook is mixed, balancing Indonesia's long-term GDP growth potential from government programs against near-term risks from currency volatility and geopolitical pressures. The ETF's dividend yield remains a draw, but a reported 27% dividend cut in 2025 signals underlying economic challenges for income-focused investors.
Zoetis (ZTS) trades at $77.13, up 4.12% in the last session, with a bearish technical signal from moving averages. The company reported strong 2025 results, including $9.47B revenue and $2.67B net income, with high profitability margins. Recent news highlights a securities class action lawsuit and the launch of Lenivia in Canada and the EU. Cash flow improved to a positive $325M in 2025, though net cash flow is projected to decline in 2026.
The stock presents a mixed outlook: strong fundamentals and a consensus price target of $101.43 suggest upside, but legal risks and bearish technicals pose near-term headwinds. Earnings momentum is key, with Q2 2026 results critical after a Q1 miss. Institutional sentiment is cautious despite no sell ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Indonesia ETF
The fund generally will invest at least 80% of its assets in the component securities of the underlying index and in investments that have economic characteristics that are substantially identical to the component securities of the underlying index. The index is a free float-adjusted market capitalization-weighted index that is designed to measure the performance of the large-, mid- and small-capitalization segments of the equity market in Indonesia. The fund is non-diversified.
Read more on EIDO →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
